Edesa Biotech Reports Fiscal 1st Quarter 2024 Results [Yahoo! Finance]
Edesa Biotech, Inc. - Common Shares (EDSA)
Company Research
Source: Yahoo! Finance
host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three months ended December 31, 2023 and provided an update on its business. During the first fiscal quarter, the company secured funding of up to C$23 million from the Canadian government toward the development of Edesa's ARDS (Acute Respiratory Distress Syndrome) drug candidate, EB05 (paridiprubart), a portion of which is conditionally repayable. Canadian regulators also approved the company's proposal to harmonize clinical trial designs in the U.S. and Canada for the current Phase 3 trial of EB05. Edesa intends to evaluate paridiprubart in a broader ARDS population as well as file an investigational new drug application (IND) for a Phase 2 study in pulmonary fibrosis. The company is planning for a Phase 2 study of its anti-CXCL10 monoclonal antibody in moderate-to-severe nonsegmental vitiligo patients. "We believe that the positive momentum that Edesa demonstrated at the beginn
Show less
Read more
Impact Snapshot
Event Time:
EDSA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EDSA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EDSA alerts
High impacting Edesa Biotech, Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
EDSA
News
- Domain Therapeutics Appoints Sean A. MacDonald as Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
- Edesa Biotech to Participate in Bloom Burton Healthcare Investor ConferenceAccesswire
- Edesa Biotech to Participate in Upcoming Investor ConferencesAccesswire
- Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory ConferenceAccesswire
- Edesa Biotech to Participate in Barclays Global Healthcare ConferenceAccesswire
EDSA
Analyst Actions
- 2/14/24 - HC Wainwright
EDSA
Sec Filings
- 4/5/24 - Form ARS
- 4/5/24 - Form DEFA14A
- 4/5/24 - Form DEF
- EDSA's page on the SEC website